SOLUBLE AND LIPOSOMAL DOXORUBICIN UPTAKE IN CANCER CELLS AFTER SHORT TERM EXPOSURE

Lavija Žibutytė1, 2, Gintaras Zaleskis1

1 Laboratory of Immunology, National Cancer Institute, Lithuania

2 Insititute of Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, Lithuania

Doxorubicin (DOX) and liposomal doxorubicin (L-DOX) are part of the anthracycline drug class, which kills cancer cells by intercalating with DNA, inhibiting topoisomerase II activity and generating reactive oxygen species. Despite being introduced more than 50 years ago, these drugs are still mainly used for treatment of solid tumors. However, doxorubicin has one key disadvantage – it possesses poor selectivity for tumor cells, which can lead to severe cardiotoxicity [1]. In order to increase selectivity of tumor cells and avoid potentially lethal side effects, researchers have incapsulated anthracycline into liposomes with polyethylene glycol (PEG) coating, thus creating liposomal doxorubicin. The size of the liposome allows greater extravasation into the tumor through vessels, meaning that L-DOX possesses greater selectivity for tumor cells than its soluble form. But the drug still has its own dose-limiting effect through palmar-plantar erythrodysesthesia. Researchers have hypothesized that the liposome of L-DOX slowly degrades and expresses its anti-tumor activity through releasing doxorubicin into the extracellular space [2]. Our working hypothesis follows this by suggesting that short term exposure to the liposomal drug may not always show high cellular uptake comparing to DOX, because of its inability to quickly accumulate in cells and release the soluble form of the drug.

In this study, we set out to compare cellular uptake of live and permeabilized tumor cells after short exposure to fresh and degraded forms of DOX and L-DOX. The degradation of drugs in tissues was simulated through keeping the drugs for several months in 37°C and protection from light. Live and permeabilized mice lymphoma SL2 cells were subjected to 10 μg/ml concentration of both drugs for 30 minutes, then washed and analyzed by flow cytometry. Results show that in both live and permeabilized cells the uptake of DOX between fresh and degraded drug does not significantly change - concentration only decreases by 1.1 times and 1.4 times, respectively, with degraded DOX. However, with L-DOX, the change in concentration is more significant – we have detected an increase of 13.3 times in live and 3.5 times in permeabilized cells, comparing the degraded drug with fresh L-DOX. Comparing the difference between uptake of DOX and L-DOX, the uptake of fresh DOX was measured 10.2 times higher in live cells and 8.6 times higher in permeabilized cells, than after incubating cells with L-DOX. With degraded drugs, uptake was 1.5 times lower and 1.8 times higher in live and permeabilized SL2 cells, respectively.

These results show that initial cellular uptake of L-DOX is significantly lower than DOX, even in permeabilized cells, which also show limited internalization of the drug. Results also suggest that while, over a short term, soluble DOX may be significantly more effective than its liposomal form, over a longer term, with liposomal degradation and slow drug release into tumor cells, L-DOX might look promising in prolonged or locoregional cancer treatment. However, this speculation still needs further study to demonstrate.


[1] J.V. McGowan, R. Chung, A. Maulik, I. Piotrowska, J. M. Walker, and D. M. Yellon, Anthracycline Chemotherapy and Cardiotoxicity, Cardiovascular Drugs and Therapy, vol. 31, 63-75, (2017).

[2] A.A. Gabizon, Y. Patil, and N.M. La-Beck, New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy, Drug Resistance Updates, vol. 29, 90-106(2016)